Transcode Therapeutics announces CFO resignation and interim appointment

Transcode Therapeutics, Inc. (NASDAQ:RNAZ) announced on September 9, 2026 that Thomas A. Fitzgerald, M.B.A. has resigned from his positions as Chief Financial Officer, principal financial officer, principal accounting officer, and board member. Fitzgerald's departure was not due to any disagreements with company operations. As part of his separation, Fitzgerald agreed to a severance package which includes a $416,666.67 lump sum payment, 12 monthly installments of the same amount, and up to an additional $416,666.67 contingent upon meeting specific funding milestones.

If the company raises $5 million or $10 million within a year, the payment terms will adjust accordingly. Fitzgerald's remaining equity awards will become fully vested and have an extended exercise period. The company will also cover his COBRA or Medicare premiums for up to 12 months, depending on eligibility. Fitzgerald will provide up to 20 hours of transitional services in September without compensation, with the option for more services at an hourly rate.

John Tattory was appointed as interim CFO, principal financial officer, and principal accounting officer, effective the same day. Tattory is a consultant through Stout Risius Ross, LLC, with experience in the pharmaceutical, medical device, and biotechnology sectors.